Pamidronate in prevention of bone complications in metastatic breast cancer: A cost-effectiveness analysis

Journal of Clinical Oncology

Volumn 18, Issue 1, 2000, Pages 72-79

  Hillner, Bruce E ^a   Weeks, Jane C ^a   Desch, Christopher E ^a   Smith, Thomas J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAMIDRONIC ACID;

ARTICLE; BONE DISEASE; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033989198     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.1.72     Document Type: Article

References (18)

1. Harris JR, Morrow M, Norton L: Malignant tumors of the breast, in Devita VT, Hellman S, Rosenberg SA. (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott, 1997, pp 1557-1616
2. Hortobagyi GN, Theriault RL, Lipton A, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases: Protocol 19 Aredia Breast Cancer Study Group [see comments]. N Engl J Med 335:1785-1791, 1996
3. Hortobagyi GN, Theriault RL, Lipton A, et al: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate: Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16:2038-2044, 1998
4. Theriault RL, Lipton A, Hortobagyi GN, et al: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial - Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17:846-854, 1999
5. United States Agency for Health Care Policy and Research: Healthcare Cost and Utilization Project. Http:www.ahcpr.gov/data/ hcup/hcupnet.htm
6. Rose CM, Kagan AR: The final report of the expert panel for the radiation oncology bone metastasis work group of the American College of Radiology. Int J Radiat Oncol Biol Phys 40:1117-1124, 1998
7. Hayman JA, Hillner BE, Harris JR, et al: Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. J Clin Oncol 16:1022-1029, 1998
8. Kristensen B, Ejlertsen B, Mouridsen HT, et al: Survival in breast cancer patients after the first episode of hypercalcaemia. J Intern Med 244:189-198, 1998
9. Weeks J: Taking quality of life into account in health economic analyses. J Natl Cancer Inst Monogr 23-27, 1996
10. Berenson JR, Lipton A: Use of bisphosphonates in patients with metastatic bone disease. Oncology (Huntingt) 12:1573-1579, 1998
11. Edelson JT, Weinstein MC, Williams L, et al: Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 263:407-413, 1990
12. Smith TJ, Hillner BE, Desch CE: Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. J Natl Cancer Inst 85:1460-1474, 1993
13. Novartis Pharmaceutical Corp: 1998 Annual Report. Http: www.novartis.com
14. Weeks JC, Tierney MR, Weinstein MC: Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 325:81-86, 1991
15. Roila F, Ballatori E: The efficacy and cost-effectiveness of various antiemetic regimens. Curr Opin Oncol 10:310-315, 1998
16. Smith TJ, Hillner BE, Schmitz N, et al: Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 15:5-10, 1997
17. Silber JH, Fridman M, Shpilsky A, et al: Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J Clin Oncol 16:2435-2444, 1998
18. Barosi G, Marchetti M, Liberato NL: Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 78:781-787, 1998